DiaMedica, Inc. (OTCQB: DMCAF) is a biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available. The company is preparing to advance its proprietary recombinant form of the naturally occurring uKLK1 into clinical testing for the treatment of stroke. It is also studying the potential of DM199 for the treatment of acute kidney injury and other vascular diseases. For more information, visit the company’s website at www.diamedica.com.
DiaMedica (DMCAF) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option